Smart, biocompatible nanoparticles can be engineered to precisely deliver extracellular-acting PFPs (e.g., PRF-1 and granulysin) directly to tumor sites or to regulate the expression and activation of intracellular PFPs (e.g., GSDMs and MLKL). This evidence concerns the gene GNLY and neoplasm.